Qure.ai is a Mumbai-headquartered healthcare AI company founded in 2016 by Prashant Warier and Dr. Pooja Rao. It builds deep-learning software that interprets medical images such as chest X-rays and head CT scans, helping clinicians triage and detect critical conditions faster. The company describes itself as one of the world's most deployed medical-imaging AI providers, with tools used across more than 90 countries spanning both high-income hospitals and resource-limited public-health programs.
Qure.ai's flagship products include qXR for chest X-ray interpretation, used widely in tuberculosis screening, and qER for head CT analysis to flag intracranial bleeds, strokes, and other emergencies. Additional offerings extend into lung-nodule management and cancer-care pathways. A defining strength is its regulatory footprint: the company has secured numerous clearances, including U.S. FDA clearances and CE marking, which are essential for clinical adoption in regulated markets.
The company has raised substantial capital to fund global expansion. In September 2024 it closed a $65 million Series D led by Lightspeed and 360 ONE Asset, with participation from Merck Global Health Innovation Fund, Kae Capital, Novo Holdings, HealthQuad, and TeamFund, bringing total funding to over $120 million. The round valued Qure.ai at roughly ₹2,230 crore and was earmarked for U.S. growth and new clinical applications.
Qure.ai's competitive moat is the combination of clinically validated models, an extensive regulatory portfolio, and large-scale real-world deployment, particularly in global health where it has screened millions for tuberculosis. The main challenges are the long sales cycles, reimbursement complexity, and rigorous validation inherent to clinical AI.
For health systems, governments, and screening programs seeking validated, deployable radiology AI, Qure.ai is among the category's most established players.